Teacher Retirement System of Texas Decreases Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Teacher Retirement System of Texas cut its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 17.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,198 shares of the company’s stock after selling 890 shares during the period. Teacher Retirement System of Texas’ holdings in Krystal Biotech were worth $521,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Jennison Associates LLC lifted its holdings in Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after purchasing an additional 383,495 shares in the last quarter. TimesSquare Capital Management LLC purchased a new position in Krystal Biotech in the 3rd quarter valued at about $14,272,000. Charles Schwab Investment Management Inc. lifted its holdings in Krystal Biotech by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 179,780 shares of the company’s stock valued at $20,854,000 after purchasing an additional 17,614 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Krystal Biotech by 40.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock valued at $278,416,000 after purchasing an additional 693,852 shares in the last quarter. Finally, Trexquant Investment LP lifted its holdings in Krystal Biotech by 8.8% in the 3rd quarter. Trexquant Investment LP now owns 8,113 shares of the company’s stock valued at $941,000 after purchasing an additional 657 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. William Blair restated an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Citigroup increased their price objective on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Guggenheim increased their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Stifel Nicolaus reiterated a “buy” rating and set a $204.00 price objective (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a report on Monday, May 6th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $177.63.

Krystal Biotech Stock Performance

KRYS opened at $162.83 on Monday. The firm has a 50 day moving average price of $166.73 and a 200 day moving average price of $138.46. The company has a market cap of $4.65 billion, a PE ratio of 87.08 and a beta of 0.91. Krystal Biotech, Inc. has a 1 year low of $93.95 and a 1 year high of $189.97.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The company had revenue of $45.25 million for the quarter, compared to analysts’ expectations of $47.37 million. The business’s quarterly revenue was up 452400.0% on a year-over-year basis. During the same period in the previous year, the business posted ($1.76) earnings per share. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 2.06 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the sale, the chief accounting officer now owns 12,936 shares of the company’s stock, valued at $2,145,823.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Krystal Biotech news, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the sale, the chief accounting officer now owns 12,936 shares of the company’s stock, valued at $2,145,823.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. Insiders sold 50,000 shares of company stock valued at $8,386,000 over the last 90 days. 14.10% of the stock is owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).